DATASHEET
Host:
Rabbit
Target Protein:
FRAT1
Immunogen Range:
161-260/279
Clonality:
Polyclonal
Isotype:
IgG
Entrez Gene:
10023
Source:
KLH conjugated synthetic peptide derived from human FRAT1
Purification:
Purified by Protein A.
Storage Buffer:
Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.
Storage:
Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles.
Background:
FRAT1 and FRAT2 were originally characterized as proteins frequently rearranged in advanced T cell lymphoma, and they have since been identified as proto-oncogenes involved in tumorigenesis. These proteins share significant homology with the Xenopus glycogen synthase kinase-3 (xGSK-3) binding protein, which is designated GBP and is essential for the formation of the dorsal-ventral axis during embryonic development. Establishment of these embryonic axes is mediated by the Wnt intracellular signaling pathway. Wnt signaling is regulated in part by the activity of GSK-3, which phosphorylates and thereby facilitates the degradation of ?catenin. GBP binds to GSK-3 and inhibits this phosphorylation, resulting in the accumulation of ?catenin and the subsequent transcription of Wnt target genes. Like GBP, FRAT2 has been shown to bind xGSK-3, suggesting that FRAT1 and FRAT2 may be GSK-3 regulatory proteins.
Conjugation:
PE
Excitation/ Emission:
496,564nm/578nm
Size:
100ul
Concentration:
1ug/ul
Applications:
WB(1:300-5000)
29
Predicted Cross Reactive Species:
Human
Mouse
Rat
Dog
Cow
For research use only. Not intended for diagnostic or therapeutic use.